A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
Titel:
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
Auteur:
Sridhar, Srikala S. Canil, Christina M. Chi, Kim N. Hotte, Sebastien J. Ernst, Scott Wang, Lisa Chen, Eric X. Juhasz, Agnes Yen, Yun Murray, Peter Zwiebel, James A. Moore, Malcolm J.